QCM
TGTX icon

Quantinno Capital Management’s TG Therapeutics TGTX Stock Holding History

Quantinno Capital Management’s Portfolio TGTX Stock Details TGTX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$2.83M Sell
51,541
-20,453
-28% -$837K ﹤0.01% 1677
2026
Q1 		$2.39M Buy
71,994
+1,476
+2% +$44K ﹤0.01% 1515
2025
Q4 		$2.1M Buy
70,518
+7,336
+12% +$240K ﹤0.01% 1343
2025
Q3 		$2.28M Buy
+63,182
New +$2.08M 0.01% 1181

Other funds holding TGTX

BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
Vanguard Portfolio Management
Vanguard Portfolio Management Malvern, Pennsylvania $2.22T AUM
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return
D.E. Shaw & Co
D.E. Shaw & Co New York $210B AUM 57.28% 1-Year Est. Return
SCM
Soleus Capital Management Greenwich, Connecticut $2.9B AUM 169.69% 1-Year Est. Return
T. Rowe Price Associates
T. Rowe Price Associates Baltimore, Maryland $999B AUM 46.22% 1-Year Est. Return
ClearBridge Investments
ClearBridge Investments New York $121B AUM 27.52% 1-Year Est. Return
CAM
Congress Asset Management Boston, Massachusetts $16.3B AUM 42.69% 1-Year Est. Return

Quantinno Capital Management's TGTX Position: Q2 2026 in Review

Quantinno Capital Management reduced its TG Therapeutics (TGTX) stake by 28% in Q2 2026, selling an estimated $837K and leaving 51,541 shares worth $2.83M. The position accounts for ﹤0.01% of the portfolio, ranked #1677.

Quantinno Capital Management first reported a position in TGTX in Q3 2025 and has held it in 4 quarters since. 430 funds tracked by Wall St. Rank hold TGTX as of Q2 2026.

  • Quantinno Capital Management held 51,541 shares of TG Therapeutics worth $2.83M as of Q2 2026.
  • Quantinno Capital Management sold 20,453 TG Therapeutics shares in Q2 2026, an estimated $837K.
  • TG Therapeutics made up ﹤0.01% of Quantinno Capital Management's portfolio in Q2 2026, its #1677 holding.
  • Quantinno Capital Management first reported a position in TG Therapeutics in Q3 2025 and has held it in 4 quarters since.
  • 430 funds tracked by Wall St. Rank held TG Therapeutics as of Q2 2026.

Based on Quantinno Capital Management's 13F filing for Q2 2026, filed 13 Aug 2026.